[1] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[2] |
CHEN Chenxin, ZHANG Pengpeng, LIU Yongmei, YE Xiaofei, HE Jia.
Combination of zero-inflated model and Dirichlet process in detection of adverse reaction signals during post-marketing surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 651-654.
|
[3] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[4] |
WANG Jiaxi, GUO Daihong, ZHANG Bo, Li Boyan, GUO Haili.
Automatic monitoring and risk factors of acute kidney injury in 116097 dosing cases of flurbiprofen axetil
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 201-205.
|
[5] |
ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing.
Advances in studies on post-market safety data sources and signal detection for medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
|
[6] |
HAO Gang, HAN Feng, ZHOU Gang, WU Xing, YAN Hao, LI Xuyang, HOU Hailing, NING Xiao, CUI Li.
Methodological study of adenosylcobalamin bacterial endotoxin examination for injection
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1351-1356.
|
[7] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[8] |
ZHONG Lumiao, DU Juan, DENG Hua, WANG Yafeng, QIU Ping, ZENG Linggui.
Thoughts on design and quality management of active safety surveillance research of traditional Chinese medicine injections initiated by Marketing Authorization Holder
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 994-998.
|
[9] |
HUANG Ying, HOU Tiantian, QIN Chao, HUO Yan, WANG Sanlong, WEN Hairuo, GENG Xingchao.
Nonclinical research on CAR-T cell products: main concerns and key issues
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 813-816.
|
[10] |
HUANG Ying, WEN Hairuo, HOU Tiantian, HUO Yan, WANG Sanlong, GENG Xingchao.
Cloning ability of CAR-T cells in soft agar and tumorigenicity in vitro
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 836-838.
|
[11] |
SHEN Chuanyong, SONG Yana, ZHAO Yan, ZHENG Lijia, ZHAO Yifei, LI Dong.
Thoughts on constructing vigilance system of Chinese medical device in the new era
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 697-701.
|
[12] |
FU Lu, PENG Huasheng, YUAN Yuan, JIN Yan.
Herbal textual research on toxicity of Zanthoxylum bungeanum
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 369-371.
|
[13] |
YANG Jingfan, XU Lu, CHEN Suiqing.
Textual research of the toxic herb Kansui Radix
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 372-375.
|
[14] |
TENG Yingying, LI Chaiquan, XU Yang, TANG Xun, GAO Pei.
Progress in the application of real-world data in post-market surveillance of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 233-238.
|
[15] |
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana.
Introduction and inspiration of international medical device regulators forum patient registry guidelines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
|